On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Cervical cancer is largely preventable, yet continues to pose a significant threat, especially to young Indian women. The time to act is now—and it begins with catching them young., Health News - Time ...

Parents asked, an expert answered. Here’s what parents learned about sex education at the Smart Parenting x Unprude event.

The drugmaker’s stock has already fallen nearly 40pc in the last 12 months, driven by uncertainty over the future of Gardasil ... a trial of an online retail brand called Joybuy ahead of ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

1436 GMT – Merck’s struggles with Gardasil aren’t easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to ...